Home > Insider Trading > Filing (0000899243-19-022791)

Filing Details

Accession Number:: 0000899243-19-022791
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-09-04 21:45:55
Reporting Period:: 2019-08-30

Accepted Time:: 2019-09-04 21:45:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1060736	Seattle Genetics Inc	SGEN	Biological Products, (No Disgnostic Substances) (2836)	911874389

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1361966	B Vaughn Himes	21823 30Th Drive Se Bothell WA 98021	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-08-30	18,013	$0.00	193,210	No	4	A	Direct
Common Stock	Acquisiton	2019-08-30	8,000	$12.00	201,210	No	4	M	Direct
Common Stock	Disposition	2019-08-30	7,287	$72.82	193,923	No	4	S	Direct
Common Stock	Disposition	2019-08-30	713	$73.24	193,210	No	4	S	Direct
Common Stock	Disposition	2019-09-03	1,814	$70.80	191,396	No	4	S	Direct
Common Stock	Disposition	2019-09-03	3,878	$70.80	187,518	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Incentive Stock Option (right to buy)	Acquisiton	2019-08-30	1,333	$0.00	1,333	$72.64
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2019-08-30	8,000	$0.00	8,000	$12.00
Common Stock	Non-Qualified Stock Option (right to buy)	Acquisiton	2019-08-30	41,453	$0.00	41,453	$72.64

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,333	2029-08-30	No	4	A	Direct
12,498	2020-08-27	No	4	M	Direct
41,453	2029-08-30	No	4	A	Direct

Footnotes

These shares represent restricted stock units and will be settled in common stock upon vesting.
Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
Shares shall vest at a rate of 25% on each anniversary of the grant date until all shares are fully vested four years from the grant date.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
Reflects sales of common stock executed in multiple transactions at prices ranging from $72.10 to $73.09. The price reported reflects the weighted average sale price. The reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of common stock executed in multiple transactions at prices ranging from $73.17 to $73.44. The price reported reflects the weighted average sale price. The reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Options vested at a rate of 25% on 8/27/11 and monthly thereafter until all the shares were fully vested on 8/27/14.
Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date.